Can Strattera Be Taken Twice Daily?

Yes, Strattera (atomoxetine) can be taken either once daily or twice daily—both dosing strategies are FDA-approved and clinically effective. 1

FDA-Approved Dosing Flexibility

The FDA label explicitly states that "STRATTERA is usually taken once or twice a day" and "STRATTERA can be taken with or without food." 1
Clinical trials have demonstrated efficacy with both once-daily morning dosing and twice-daily divided dosing (early morning and late afternoon/early evening). 1
The choice between once-daily versus twice-daily dosing should be based on tolerability, symptom coverage needs, and individual patient response. 1

A 6-week pediatric trial (N=171) demonstrated that once-daily morning administration (mean dose 1.3 mg/kg/day) significantly improved ADHD symptoms compared to placebo, confirming that "STRATTERA is effective when administered once daily in the morning." 1
Once-daily dosing provides around-the-clock symptom control throughout the waking day and into the evening, reducing the need for multiple doses. 2
This approach offers practical advantages including simplified medication adherence and elimination of school-day dosing. 2

Multiple FDA trials used divided dosing (early morning and late afternoon/early evening) with doses ranging from 1.2 to 1.8 mg/kg/day, demonstrating superior efficacy over placebo. 1
In a pediatric study (N=55), switching from once-daily to twice-daily dosing at midpoint was associated with significant improvement in oppositional defiant disorder symptoms at home (p<0.05) and decreased rates of stomachaches (p<0.05). 3
An adult study (N=218) comparing 80 mg once-daily versus 40 mg twice-daily found that twice-daily dosing resulted in significantly lower frequency of nausea (16.4% vs 32.4%; p=0.007), though both strategies were safe, well-tolerated, and efficacious. 4

When to prefer once-daily dosing:

When to consider twice-daily dosing:

Gastrointestinal side effects (particularly nausea) with once-daily dosing—splitting the dose may improve tolerability 4
Inadequate symptom control in late afternoon/evening with once-daily dosing 3
Comorbid oppositional defiant disorder symptoms requiring additional home coverage 3
Stomachaches or other tolerability issues with once-daily dosing 3

Dose switching flexibility: The evidence indicates that changes in dosing strategy (once-daily to twice-daily or vice versa) are unlikely to be accompanied by safety risks, allowing prescribers to use discretion based on individual patient factors. 4
Sleep considerations: Atomoxetine administered twice-daily has been shown to have shorter sleep-onset latencies compared to thrice-daily methylphenidate, based on objective actigraphy and polysomnography data. 5
Timing of second dose: When using twice-daily dosing, the FDA label and clinical trials specify administration in "early morning and late afternoon/early evening" rather than bedtime. 1
Total daily dose remains the same: Whether given once or twice daily, the target therapeutic dose (typically 1.2-1.8 mg/kg/day in children, up to 100 mg/day in adults) remains unchanged—only the timing of administration differs. 1, 6